These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2567038)

  • 1. Animal models for anxiety and response to serotonergic drugs.
    Broekkamp CL; Berendsen HH; Jenck F; Van Delft AM
    Psychopathology; 1989; 22 Suppl 1():2-12. PubMed ID: 2567038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new generation of serotonergic anxiolytics: possible clinical roles.
    Eison MS
    Psychopathology; 1989; 22 Suppl 1():13-20. PubMed ID: 2567037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin receptor subtypes: implications for psychopharmacology.
    Cowen PJ
    Br J Psychiatry Suppl; 1991 Sep; (12):7-14. PubMed ID: 1840764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of pharmacological agents that act at serotonin receptors.
    Peroutka SJ; Sleight AJ; McCarthy BG; Pierce PA; Schmidt AW; Hekmatpanah CR
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):253-62. PubMed ID: 2562495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes.
    Gleeson S; Ahlers ST; Mansbach RS; Foust JM; Barrett JE
    J Pharmacol Exp Ther; 1989 Sep; 250(3):809-17. PubMed ID: 2476547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurobiologic basis of anxiety and its treatment.
    Salzman C; Miyawaki EK; le Bars P; Kerrihard TN
    Harv Rev Psychiatry; 1993; 1(4):197-206. PubMed ID: 9384849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.
    Griebel G
    Pharmacol Ther; 1995 Mar; 65(3):319-95. PubMed ID: 7644567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anxiolytics in development.
    Mosconi M; Chiamulera C; Recchia G
    Int J Clin Pharmacol Res; 1993; 13(6):331-44. PubMed ID: 7916335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
    Moulignier A
    Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
    Millan MJ; Bervoets K; Colpaert FC
    J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral studies of serotonin receptor agonists as antidepressant drugs.
    Lucki I
    J Clin Psychiatry; 1991 Dec; 52 Suppl():24-31. PubMed ID: 1684363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of serotonin in therapy of depression and related disorders.
    Fuller RW
    J Clin Psychiatry; 1991 May; 52 Suppl():52-7. PubMed ID: 1674251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans?
    Berendsen HH
    Pharmacol Ther; 1995 Apr; 66(1):17-37. PubMed ID: 7630928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses?
    Montgomery SA; Fineberg N
    Br J Psychiatry Suppl; 1989 Dec; (8):63-9. PubMed ID: 2692641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azapirones: history of development.
    Eison AS
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):2S-5S. PubMed ID: 1973936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
    Kleven MS; Assié MB; Koek W
    J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.
    Barrett JE; Vanover KE
    Psychopharmacology (Berl); 1993; 112(1):1-12. PubMed ID: 7870996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and alcohol: interrelationships.
    Tollefson GD
    Psychopathology; 1989; 22 Suppl 1():37-48. PubMed ID: 2567040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery.
    Hamel E; Robert JP; Young AR; MacKenzie ET
    J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic mechanisms in anxiety.
    Eison AS; Eison MS
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan; 18(1):47-62. PubMed ID: 8115673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.